Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan as combined PET-CT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis

Surgery is the mainstay of treatment for vulvar cancer. FIGO staging requires histopathological detail of the primary tumor and inguinofemoral lymph nodes but groin node dissection carries a substantial risk of short and long-term morbidity. The trend in current practice is towards sentinel lymphadenectomy for cancers with a low risk of metastases. Full lymphadenectomy is undertaken if the sentinel lymph node contains metastasis. The predictive value of 18F-FDG-PET in preoperative assessment of the groin in vulvar squamous cancer was assessed in retrospect at a single institution. A period of three years prior to the introduction of sentinel lymph node mapping was chosen in order to have full histopathological assessment of inguinal and femoral lymph nodes available as the gold standard for correlation with positron emission tomography-computerized tomography (PET-CT) to determine the accuracy of the enhanced radiological technique. In patients with histologically proven metastases to groin nodes, comparisons between PET-CT positive (True-posi-tive/TP) and negative (False-negative/FN) groups vis-à-vis histology showed a tendency towards higher FDG avidity in the vulvar lesions, more bilateral nodes, multiple metastases, larger metastases and more extra-capsular extension in the TP group. Calculations per patient for PET-CT yielded a sensitivity of 50% and specificity at 100%. The positive predictive value (PPV) was 100% and the negative predictive value (NPV) was 57.1%. The test accuracy was 70% per patient. The high positive predictive value of PET-CT can be used to advance treatment planning prior to surgical staging of patients identified with Stage III disease. The poor sensitivity makes it unsuitable as a substitute for staging lymphadenectomy.

PET-CT; Vulvar Cancer; Specificity; Positive Predictive Value.

[1] Ghurani G.B., Penalver M.A.: “An update on vulvar cancer”. Am. J. Obstet. Gynecol., 2001, 185, 294.

[2] Saraiya M., Watson M., Wu X., King J.B., Chen V.W., Smith J.S., et al.: “Incidence of in situ and invasive cancer in the US, 1998-2003”. Cancer, 2008, 113, 2865.

[3] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[4] Woelber L., Eulenburg C., Choschzick M., Kruell A., Petersen C., Gieseking F., et al.: “Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment”. Int. J. Gy-necol. Cancer, 2012, 22, 503.

[5] Arango H.A., Hoffman M.S., Roberts W.S., Decesare S.L., Fiorica J. V., Drake J.: “Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies”. Obstet. Gynecol., 2000, 95, 553.

[6] Abang Mohammed D.K., Uberoi R., de B Lopes A., Monaghan J.M.: “Inguinal node status by ultrasound in vulva cancer”. Gynecol. Oncol., 2000, 77, 93.

[7] Mäkelä P.J., Leminen A., Kääriäinen M., Lehtovirta P.: “Pretreatment sonographic evaluation of inguinal lymph nodes in patients with vulvar malignancy”. J. Ultrasound Med., 1993, 12, 255.

[8] Hall T.B., Barton D.P., Trott P.A., Nasiri N., Shepherd J.H., Thomas J. M., et al.: “The role of ultrasound-guided cytology of groin lymph nodes in the management of squamous cell carcinoma of the vulva: 5-year experience in 44 patients”. Clin. Radiol., 2003, 58, 367.

[9] Sohaib S.A., Richards P.S., Ind T., Jeyarajah A.R., Shepherd J.H., Jacobs I.J., et al.: “MR imaging of carcinoma of the vulva”. Am. J. Roentgenol, 2002,178, 373.

[10] Hawnaur JM, Reynolds K, Wilson G, Hillier V, Kitchener HC. Identification of inguinal lymph node metastases from vulval carcinoma by magnetic resonance imaging: an initial report. Clin. Radiol., 2002, 57, 995.

[11] Singh K., Orakwue C.O., Honest H., Balogun M., Lopez C., Luesley D.M.: “Accuracy of magnetic resonance imaging of inguinofemoral lymph nodes in vulval cancer”. Int. J. Gynaecol. Cancer, 2006, 16, 1179.

[12] Selman T.J., Luesley D.M., Acheson N., Khan K.S., Mann C.H.: “A systematic review of the accuracy of diagnostic tests for inguinal lymph node status in vulvar cancer”. Gynecol. Oncol., 2005, 99, 206.

[13] Weber W.A., Avril N., Schwaiger M.: “Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol., 1999, 175, 356.

[14] Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clin-ical study in melanoma. J. Nucl. Med., 2000, 41, 1491.

[15] Havenga K., Cobben D.C., Oyen W.J., Nienhuijs S., Hoekstra H.J., Ruers T.J., et al.: “Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma”. Eur. J. Surg. Oncol., 2003, 29, 662.

[16] Braams J.W., Pruim J., Nikkels P.G.J., Roodenburg J.L.N., Vaalburg W., Vermey A.: “Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-Tyrosine, MRI and CT”. J. Nucl. Med., 1996, 37, 897.

[17] Hoffman J.M., Hanson M.W., Coleman R.E.: “Clinical positron emission tomography imaging”. Radiol. Clin. North Am., 1993, 4, 935.

[18] Grigsby P.W., Siegel B.A., Dehdashti F.: “Lymph node staging by positron emission tomography in patients with carcinoma of the cervix”. J. Clin. Oncol., 2001, 19, 3745.

[19] Scheidler J., Hricak H., Yu K.K., Subak L., Segal M.R.: “Radiological evaluation of lymph node metastases in patients with cervical cancer: a meta analysis”. JAMA., 1997, 278, 1096.

[20] Chung H.H., Jo H., Kang W.J., Kim J.W., Park N.H., Song Y.S., et al.: “Clinical impact of intergrated PET/CT on the magagement of suspected cervical cancer recurrence”. Gynecal. Oncol., 2007, 104, 529.

[21] Yildirim Y., Sehirali S., Avci M.E., Yilmaz C., Ertopcu K., Tinar S., et al.: “Integrated PET/CT for the evaluation of paraaortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings”. Gynecol. Oncol., 2008, 108, 154.

[22] Kidd E.A., Siegel B.A., Dehdashti, Rader J.S., Mutch D.G., Powell M. A., et al.: “Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J. Clin. Oncol., 2010, 28, 2108.

[23] Leblanc E., Gauthier H., Querleu D., Ferron G., Zerdoud S., Morice P., et al.: “Accuracy of 18-Fluro-2-deoxy-D-glucose Position Emission Tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma”. Ann. Surg. Oncol., 2011, 18, 2302.

[24] De Hullu J.A., Pruim J., Qué T.H., Aalders J.G., Boonstra H., Vaalburg W., et al.: “Noninvasive detection of inguinofemoral lymph node metastases in squamous cell cancer of the vulva by L-[1-11C]-tyrosine positron emission tomography”. Int. J. Gynecol. Cancer, 1999, 9, 141.

[25] Cohn D.E., Dehdashti F., Gibb R.K., Mutch D.G., Rader J.S., Siegel B. A., et al.: “Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer”. Gynecol. Oncol., 2002, 85, 179.

[26] Ansink A.C., van Tinteren H., Aartsen E.J., Heintz A.P.: “Outcome, complications and follow-up in surgically treated squamous cell car-cinoma of the vulva 1956-1982”. Eur. J. Obstet. Gynecol. Reprod. Biol., 1991, 42, 137.

[27] Gaarenstroom K.N., Kenter G.G., Trimbos J.B., Agous I., Amant F., Peters A.A., et al.: “Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int. J. Gynecol. Cancer, 2003, 13, 522.

[28] De Hullu J.A., Ansink A.C., Tymstra T., van der Zee A.G.: “What doctors and patients think about false-negative sentinel lymph nodes in vulvar cancer2. J. Psychosom Obstet. Gynaecol., 2001, 22, 199.

[29] Burger M.P.M., Hollema H., Bouma J.: “The side of groin node metastases in unilateral vulvar carcinoma”. Int. J. Gynecol. Cancer, 1996, 6, 318.

[30] Levenback C., Burke T.W., Morris M., Malpica A., Lucas K.R., Gershenwald D.M.: “Potential applications of intraoperative lymphatic mapping in vulvar cancer”. Gynecol. Oncol., 1995, 59, 216.

[31] Rodier J.F., Janser J.C., Routiot T., David E., Ott G., Schneegans O., et al.: “Sentinel node biopsy in vulvar malignancies: a preliminary feasibility study”. Oncol. Rep., 1999, 6, 1249.

[32] Ansink A.C., Sie-Go D.M.D.S., van der Velden J., Sijmons E.A., de Barros Lopes A., Monaghan J.M., et al.: “Identification of sentinel lymph nodes in vulvar carcinoma patients with the aid of a patent blue V injection”. Cancer, 1999, 86, 652.

[33] De Cicco C., Sideri M., Bartolomei M., Grana C., Cremonesi M., Fiorenza M., et al. “Sentinel node biopsy in early vulvar cancer”. Br. J. Cancer, 2000, 82, 295.

[34] de Hullu J.A., Hollema H., Piers D.A., Verheijen R.H., van Diest P.J., Mourits M.J., et al.: “Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva”. J. Clin. Oncol., 2000, 18, 2811.

[35] Levenback C., Coleman R.L., Burke T.W., Bodurka-Bevers D., Wolf J. K., Gershenwald D.M.: “Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer”. Gynecol. Oncol., 2001, 83, 276.

[36] Moore R.G., DePasquale S.E., Steinhoff M.M., Gajewski W., Steller M., Noto R., et al.: “Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva2. Gynecol. Oncol., 2003, 89, 475.

[37] Oonk M., De Hullu J., Ansink A., Vergote I., Verheijen R., Maggioni A., et al.: “Chances for additional metastases in vulvar cancer patients with a positive sentinel lymph node (SN)”. Int. J. Gynecol. Cancer, 2005, 15, 51.

[38] Grimshaw R.N., Murdoch J.B., Monaghan J.M.: “Radical vulvectomy and bilateral inguinal-femoral lymphadenectomy through separate incisions-experience with 100 cases”. Int. J. Gynecol. Cancer, 1993, 3, 18.

[39] Falconer A.D., Hirschowitz L., Weeks J., Murdoch J.: “South West Gynaecology Tumour Panel. The impact of improving outcomes guidance on surgical management of vulval squamous cell cancer in southwest England (1997-2002)”. BJOG., 2007, 114, 391.

[40] Ramanah R., Lesieur B., Ballester M., Darai E., Rouzier R.: “Trends in of late-stage squamous cell vulvar carcinomas: analysis of the surveillance, epidemiology, and end results (SEER) database”. Int. J. Gynecol. Cancer, 2012, 22, 854.

[41] Oonk M.H., Hollema H., de Hullu J.A., van der Zee A.G.: “Prediction of lymph node metastases in vulvar cancer: a review. Int. J. Gynecol. Cancer, 2006, 16, 963.

[42] Perez C.A., Grigsby P.W., Galakatos A., Swanson R., Camel H.M., Kao M. S., et al.: “Radiation therapy in management of carcinoma of the vulva with emphasis on conservation therapy”. Cancer, 1993, 71, 3707.

[43] Moore D.H.: “Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?” Gynecol. Oncol., 2009, 113, 379.

[44] Courtney-Brooks M., Sukumvanich P., Beriwal S., Zorn K.K., Richard S.D., Krivak T.C.: “Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease?” Gynecol. Oncol., 2010, 117, 308.

[45] Stehman F.B., Bundy B.N., Thomas G., Varia M., Okagaki T., Roberts J., et al.: “Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study”. Int. J. Radiat. Oncol. Biol. Phys., 1992, 24, 389.

[46] Onal C., Oymak E., Findikcioglu A., Reyhan M.: “Isolated mediastinal lymph node false positivity of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical cancer”. Int. J. Gynecol. Cancer, 2013, 23, 337.

[47] Coulter J., Gleeson N.: “Local and regional recurrence of vulval cancer: management dilemmas”. Best Pract. Res. Clin. Obstet. Gynaecol., 2003, 17, 663.